GW & Wade’s AbbVie ABBV Stock Holding History

GW & Wade’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$6.68M	Buy	43,099 +2,419	+6%	+$353K	0.22%	91
2023 Q3	$6.06M	Sell	40,680 -562	-1%	-$82.5K	0.23%	88
2023 Q2	$5.56M	Sell	41,242 -2,179	-5%	-$320K	0.2%	87
2023 Q1	$6.92M	Sell	43,421 -57	-0.1%	-$8.71K	0.27%	79
2022 Q4	$7.03M	Buy	43,478 +5,683	+15%	+$871K	0.29%	73
2022 Q3	$5.07M	Sell	37,795 -1,116	-3%	-$160K	0.25%	77
2022 Q2	$5.96M	Buy	38,911 +282	+0.7%	+$43.1K	0.27%	72
2022 Q1	$6.26M	Buy	38,629 +305	+0.8%	+$44.3K	0.27%	76
2021 Q4	$5.19M	Buy	38,324 +2,333	+6%	+$276K	0.23%	79
2021 Q3	$3.88M	Buy	35,991 +1,497	+4%	+$171K	0.18%	90
2021 Q2	$3.88M	Sell	34,494 -1,162	-3%	-$131K	0.19%	88
2021 Q1	$3.86M	Buy	35,656 +12,411	+53%	+$1.33M	0.21%	84
2020 Q4	$2.49M	Buy	23,245 +8,943	+63%	+$859K	0.15%	91
2020 Q3	$1.25M	Buy	14,302 +34	+0.2%	+$3.2K	0.1%	105
2020 Q2	$1.4M	Buy	14,268 +1,061	+8%	+$93.4K	0.11%	97
2020 Q1	$1.01M	Buy	13,207 +2,783	+27%	+$237K	0.09%	106
2019 Q4	$923K	Buy	10,424 +697	+7%	+$57.9K	0.07%	125
2019 Q3	$736K	Buy	9,727 +366	+4%	+$25.1K	0.06%	128
2019 Q2	$681K	Sell	9,361 -1,535	-14%	-$121K	0.06%	134
2019 Q1	$878K	Sell	10,896 -3,176	-23%	-$260K	0.08%	117
2018 Q4	$1.3M	Buy	14,072 +1,486	+12%	+$131K	0.14%	98
2018 Q3	$1.19M	Sell	12,586 -1,052	-8%	-$99.8K	0.13%	105
2018 Q2	$1.26M	Buy	13,638 +4,793	+54%	+$468K	0.14%	100
2018 Q1	$837K	Sell	8,845 -6	-0.1%	-$659	0.1%	116
2017 Q4	$856K	Sell	8,851 -24	-0.3%	-$2.26K	0.1%	108
2017 Q3	$789K	Sell	8,875 -414	-4%	-$31.5K	0.1%	110
2017 Q2	$674K	Buy	9,289 +11	+0.1%	+$740	0.09%	117
2017 Q1	$605K	Buy	9,278 +243	+3%	+$15.3K	0.08%	122
2016 Q4	$566K	Sell	9,035 -287	-3%	-$17.5K	0.09%	122
2016 Q3	$588K	Buy	9,322 +225	+2%	+$14.6K	0.11%	114
2016 Q2	$563K	Sell	9,097 -40	-0.4%	-$2.44K	0.1%	132
2016 Q1	$522K	Sell	9,137 -3,327	-27%	-$185K	0.1%	115
2015 Q4	$738K	Buy	12,464 +3,544	+40%	+$204K	0.16%	101
2015 Q3	$485K	Buy	8,920 +288	+3%	+$18.7K	0.11%	118
2015 Q2	$580K	Sell	8,632 -149	-2%	-$9.73K	0.11%	121
2015 Q1	$514K	Buy	+8,781	New	+$530K	0.1%	131
2014 Q1	–	Sell	-70,806	Closed	-$3.74M	–	75
2013 Q4	$3.74M	Sell	70,806 -1,406	-2%	-$69.1K	1.21%	33
2013 Q3	$3.23M	Buy	72,212 +1,747	+2%	+$77.4K	1.12%	39
2013 Q2	$2.91M	Buy	+70,465	New	+$3.08M	1.05%	40

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GW & Wade's ABBV Position: Q4 2023 in Review

GW & Wade increased its AbbVie (ABBV) stake by 5.9% in Q4 2023, buying an estimated $353K and bringing the position to 43,099 shares worth $6.68M. The position accounts for 0.22% of the portfolio, ranked #91.

GW & Wade first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $7.03M in Q4 2022. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

GW & Wade held 43,099 shares of AbbVie worth $6.68M as of Q4 2023.
GW & Wade bought 2,419 AbbVie shares in Q4 2023, an estimated $353K.
AbbVie made up 0.22% of GW & Wade's portfolio in Q4 2023, its #91 holding.
GW & Wade first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
GW & Wade's AbbVie position peaked at $7.03M in Q4 2022.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.